[5-Fluorocytosine and combinations].
The antimycotic and pharmacological properties of 5-fluorocytosine are presented. Especially the aspect of good gastrointestinal absorption, elimination by the kidney, unwanted side effects and appearance of primary and secondary resistance are discussed. The indication of 5 FC monotherapy or combination therapy is shown in various manifestations of deep candidiasis.
Polak
A
A
F. Hoffmann-La Roche, Recherche Pharmaceutique, Bâle, Suisse.
D000935:Antifungal Agents / Q000627:therapeutic use; D002177:Candidiasis / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005437:Flucytosine / Q000627:therapeutic use*; D006801:Humans
D000935:Antifungal Agents; D005437:Flucytosine
5-Fluorocytosine et associations.